CO2018004857A2 - Dihydroimidazopirazinone derivatives used in cancer treatment - Google Patents
Dihydroimidazopirazinone derivatives used in cancer treatmentInfo
- Publication number
- CO2018004857A2 CO2018004857A2 CONC2018/0004857A CO2018004857A CO2018004857A2 CO 2018004857 A2 CO2018004857 A2 CO 2018004857A2 CO 2018004857 A CO2018004857 A CO 2018004857A CO 2018004857 A2 CO2018004857 A2 CO 2018004857A2
- Authority
- CO
- Colombia
- Prior art keywords
- dihydroimidazopirazinone
- cancer treatment
- derivatives used
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere a compuestos de Fórmula (I) (I) o sales farmacéuticamente aceptables de los mismos, en la que R1, R2 y R3 tienen cualquiera de los significados definidos anteriormente en el presente documento en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento del cáncer.The present description refers to compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252726P | 2015-11-09 | 2015-11-09 | |
| US201662401351P | 2016-09-29 | 2016-09-29 | |
| PCT/EP2016/076932 WO2017080979A1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018004857A2 true CO2018004857A2 (en) | 2018-07-19 |
Family
ID=57241113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0004857A CO2018004857A2 (en) | 2015-11-09 | 2018-05-07 | Dihydroimidazopirazinone derivatives used in cancer treatment |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9902731B2 (en) |
| EP (1) | EP3374359B1 (en) |
| JP (1) | JP6877423B2 (en) |
| KR (1) | KR20180074788A (en) |
| CN (1) | CN108349983B (en) |
| AU (1) | AU2016351813B2 (en) |
| BR (1) | BR112018008397B1 (en) |
| CA (1) | CA3003549A1 (en) |
| CL (1) | CL2018001226A1 (en) |
| CO (1) | CO2018004857A2 (en) |
| CR (1) | CR20180316A (en) |
| CY (1) | CY1123627T1 (en) |
| DK (1) | DK3374359T3 (en) |
| EA (1) | EA038028B1 (en) |
| ES (1) | ES2780650T3 (en) |
| HR (1) | HRP20200342T1 (en) |
| IL (1) | IL258953A (en) |
| LT (1) | LT3374359T (en) |
| ME (1) | ME03770B (en) |
| MX (1) | MX376639B (en) |
| MY (1) | MY197626A (en) |
| NI (1) | NI201800058A (en) |
| PE (1) | PE20181288A1 (en) |
| PH (1) | PH12018500987A1 (en) |
| PL (1) | PL3374359T3 (en) |
| PT (1) | PT3374359T (en) |
| RS (1) | RS60155B1 (en) |
| SG (1) | SG11201803066VA (en) |
| SI (1) | SI3374359T1 (en) |
| SM (1) | SMT202000152T1 (en) |
| SV (1) | SV2018005687A (en) |
| TN (1) | TN2018000119A1 (en) |
| TW (1) | TWI730012B (en) |
| WO (1) | WO2017080979A1 (en) |
| ZA (1) | ZA201803742B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3365334T3 (en) | 2015-10-21 | 2024-11-25 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| PE20181288A1 (en) * | 2015-11-09 | 2018-08-07 | Astrazeneca Ab | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USED IN THE TREATMENT OF CANCER |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| JP7352981B2 (en) * | 2018-10-10 | 2023-09-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | Dihydroimidazopyrazinone compounds, compositions containing the compounds and uses thereof |
| TW202102511A (en) | 2019-03-28 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | A thienyl fused heterocyclic derivative, a preparation method thereof, and medical applications thereof |
| CN113825757B (en) | 2019-05-24 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | Substituted fused bicyclic derivatives, their preparation methods and their applications in medicine |
| CA3140475A1 (en) | 2019-06-06 | 2020-12-10 | Wei-Guo Su | Tricyclic compounds and their use |
| CA3157504A1 (en) * | 2019-12-05 | 2021-06-10 | Astrazeneca Ab | Process and intermediates for the production of formula (i) |
| AU2020398022B2 (en) * | 2019-12-06 | 2023-04-27 | D3 Bio (Wuxi) Co., Ltd. | Thiazololactam compound as ERK inhibitor and use thereof |
| EP4223758A4 (en) | 2020-09-29 | 2024-04-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | CRYSTALLINE FORM OF A HETEROCYCLIC PYRROL DERIVATIVE AND METHOD FOR PREPARING IT |
| AR126166A1 (en) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES OF THESE |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| CN117677398A (en) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | Medicines for the treatment and/or prevention of cancer |
| WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
| WO2023212237A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20250304593A1 (en) | 2022-05-12 | 2025-10-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US7485640B2 (en) * | 2002-11-06 | 2009-02-03 | Merck Sharp & Dohme Limited | Imidazopyrazinones as GABA-A receptor anxiolytics |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| JP5178738B2 (en) * | 2006-12-20 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel JNK inhibitor |
| US9840507B2 (en) * | 2010-12-22 | 2017-12-12 | Janssen Pharmaceutica, Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| HK1211023A1 (en) * | 2011-10-10 | 2016-05-13 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| JP2013166727A (en) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | Dihydroimidazo pyrazinone derivative |
| SI2820009T1 (en) | 2012-03-01 | 2018-05-31 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (en) * | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | Serine / threonine kinase inhibitor |
| KR102379517B1 (en) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | Serine/threonine kinase inhibitors |
| KR102396710B1 (en) | 2013-12-30 | 2022-05-10 | 어레이 바이오파마 인크. | Serine/threonine kinase inhibitors |
| AR099989A1 (en) | 2014-04-09 | 2016-08-31 | Genentech Inc | PREPARATION PROCESS OF (S) -1- (1- (4-CHLORO-3-FLUOROPHENYL) -2-HYDROXYETHYL) -4- (2 - ((1-METHYL-1H-PIRAZOL-5-IL) AMINO) PIRIMIDIN -4-IL) -2 (1H) -ONA AND ITS SALTS |
| US10412619B2 (en) * | 2014-11-14 | 2019-09-10 | Qualcomm Incorporated | Buffer status report for eDCS |
| WO2016162325A1 (en) * | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| EP3303335B1 (en) | 2015-06-03 | 2021-07-28 | JS Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| CN107849046B (en) | 2015-06-03 | 2020-06-12 | 常州捷凯医药科技有限公司 | Heterocyclic compounds as ERK inhibitors |
| PE20181288A1 (en) * | 2015-11-09 | 2018-08-07 | Astrazeneca Ab | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USED IN THE TREATMENT OF CANCER |
-
2016
- 2016-11-08 PE PE2018000611A patent/PE20181288A1/en unknown
- 2016-11-08 SM SM20200152T patent/SMT202000152T1/en unknown
- 2016-11-08 CA CA3003549A patent/CA3003549A1/en active Pending
- 2016-11-08 AU AU2016351813A patent/AU2016351813B2/en active Active
- 2016-11-08 TW TW105136236A patent/TWI730012B/en not_active IP Right Cessation
- 2016-11-08 SI SI201630668T patent/SI3374359T1/en unknown
- 2016-11-08 PL PL16791420T patent/PL3374359T3/en unknown
- 2016-11-08 DK DK16791420.9T patent/DK3374359T3/en active
- 2016-11-08 EP EP16791420.9A patent/EP3374359B1/en active Active
- 2016-11-08 US US15/345,537 patent/US9902731B2/en active Active
- 2016-11-08 MY MYPI2018000675A patent/MY197626A/en unknown
- 2016-11-08 TN TNP/2018/000119A patent/TN2018000119A1/en unknown
- 2016-11-08 WO PCT/EP2016/076932 patent/WO2017080979A1/en not_active Ceased
- 2016-11-08 CR CR20180316A patent/CR20180316A/en unknown
- 2016-11-08 ES ES16791420T patent/ES2780650T3/en active Active
- 2016-11-08 PT PT167914209T patent/PT3374359T/en unknown
- 2016-11-08 MX MX2018005725A patent/MX376639B/en active IP Right Grant
- 2016-11-08 EA EA201891063A patent/EA038028B1/en unknown
- 2016-11-08 KR KR1020187016091A patent/KR20180074788A/en not_active Withdrawn
- 2016-11-08 BR BR112018008397-6A patent/BR112018008397B1/en active IP Right Grant
- 2016-11-08 HR HRP20200342TT patent/HRP20200342T1/en unknown
- 2016-11-08 ME MEP-2020-72A patent/ME03770B/en unknown
- 2016-11-08 CN CN201680064567.2A patent/CN108349983B/en active Active
- 2016-11-08 JP JP2018522784A patent/JP6877423B2/en active Active
- 2016-11-08 SG SG11201803066VA patent/SG11201803066VA/en unknown
- 2016-11-08 RS RS20200392A patent/RS60155B1/en unknown
- 2016-11-08 LT LTEP16791420.9T patent/LT3374359T/en unknown
-
2018
- 2018-01-18 US US15/873,965 patent/US10202391B2/en active Active
- 2018-04-26 IL IL258953A patent/IL258953A/en active IP Right Grant
- 2018-05-03 NI NI201800058A patent/NI201800058A/en unknown
- 2018-05-07 SV SV2018005687A patent/SV2018005687A/en unknown
- 2018-05-07 PH PH12018500987A patent/PH12018500987A1/en unknown
- 2018-05-07 CL CL2018001226A patent/CL2018001226A1/en unknown
- 2018-05-07 CO CONC2018/0004857A patent/CO2018004857A2/en unknown
- 2018-06-06 ZA ZA2018/03742A patent/ZA201803742B/en unknown
-
2020
- 2020-04-02 CY CY20201100314T patent/CY1123627T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004857A2 (en) | Dihydroimidazopirazinone derivatives used in cancer treatment | |
| CY1124726T1 (en) | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | |
| UY35590A (en) | NEW COMPOUNDS FOR CANCER TREATMENT | |
| CL2019001077A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo [4,3-f] isoquinoline derivatives useful in the treatment of cancer. | |
| CL2018003681A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CO2017002998A2 (en) | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein | |
| MX2019012847A (en) | C5-anilinoquinazoline compounds and their use in treating cancer. | |
| NI201700169A (en) | CYCLED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE OF THEM AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
| NI201600115A (en) | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B. | |
| NI201600018A (en) | PYRROLAMIDE DERIVATIVES SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B. | |
| MX2016014547A (en) | Compounds for treating spinal muscular atrophy. | |
| MX372716B (en) | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| ECSP15014941A (en) | ANTI-VIRUS COMPOUNDS FOR RSV | |
| NI201500096A (en) | CHEMICAL COMPOUNDS | |
| UY36875A (en) | BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES | |
| NI201600176A (en) | COMPOUNDS OF 1, 3, 4 - TIADIAZOLE AND THE USE OF THEM FOR THE TREATMENT OF CANCER. | |
| CL2017000682A1 (en) | Novel imidazopyridazine compounds and their use. | |
| UY38228A (en) | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| PE20151607A1 (en) | ORGANIC COMPOUND FORMULATIONS | |
| DOP2017000018A (en) | [1,2,4] TRIAZOLO [4,3-B] PIRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
| ECSP18056196A (en) | DERIVATIVES OF INDANO | |
| UY36464A (en) | QUINAZOLINE COMPOUNDS |